Newstral
David Alexandre Gros
- MNeurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as expectedmarketwatch.com
- Alnylam soars as Sanofi weighs its optionsThe Salt Lake Tribune
- Top former Sanofi executive to join Cambridge drugmaker Alnylambizjournals.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.